文献速递头颈外科

黏膜头颈部鳞状细胞癌手术前新辅助免疫治疗:系统综述

Neoadjuvant immunotherapy prior to surgery for mucosal head and neck squamous cell carcinoma: Systematic review.
PubMed 文献 · Head Neck · 2021-11-26

本系统综述检索了Pubmed、Embase、Cochrane Library、Web of Science、Google Scholar和clinicaltrials.gov,纳入8项新辅助头颈癌免疫治疗临床试验共260例患者,研究药物包括纳武利尤单抗、帕博利珠单抗、伊匹木单抗、度伐利尤单抗和替西木单抗。总体平均客观缓解率(ORR)为45.9 ± 5.7%,单药平均ORR为41.5 ± 5.6%,无因免疫相关毒性导致的死亡。作者结论认为新辅助免疫治疗在I/II期临床试验中显示出良好缓解率且无意外免疫相关毒性。

要点

  • 8项I/II期临床试验共260例患者接受新辅助免疫检查点抑制剂治疗。
  • 总体平均ORR为45.9 ± 5.7%,单药平均ORR为41.5 ± 5.6%。
  • 无因免疫相关毒性导致的死亡。

核心结论

  • 新辅助免疫治疗用于黏膜头颈部鳞状细胞癌在I/II期临床试验中显示出良好缓解率,且无意外免疫相关毒性。

研究设计与样本

  • 系统综述,检索Pubmed、Embase、Cochrane Library、Web of Science、Google Scholar和clinicaltrials.gov,纳入8项新辅助头颈癌免疫治疗临床试验,共260例患者。

主要发现

  • 研究药物包括纳武利尤单抗、帕博利珠单抗、伊匹木单抗、度伐利尤单抗和替西木单抗。
  • 总体平均客观缓解率(ORR)为45.9 ± 5.7%,单药平均ORR为41.5 ± 5.6%。
  • 无因免疫相关毒性导致的死亡。

关键数值与推荐

  • 总体平均ORR为45.9 ± 5.7%,单药平均ORR为41.5 ± 5.6%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Given the recent successes of anti-PD-1 immunotherapy, many clinical trials have sought to assess the safety and efficacy of this treatment modality in the neoadjuvant setting. This systematic review provides a comprehensive summary of findings from neoadjuvant head and neck cancer immunotherapy clinical trials with a focus on PD-1/PD-L1 axis blockade. Pubmed, Embase, Cochrane Library, Web of Science, Google Scholar, and clinicaltrials.gov were systematically searched for all eligible neoadjuvant head and neck cancer immunotherapy clinical trials. Eight clinical trials met the inclusion criteria comprising a total of 260 patients. Study drugs included nivolumab, pembrolizumab, ipilimumab, durvalumab, and tremelimumab. The overall mean objective response rate (ORR) was 45.9 ± 5.7% with a 41.5 ± 5.6% single agent mean ORR. There were no deaths due to immune-related toxicities. Neoadjuvant immunotherapy for mucosal head and neck squamous cell cancer has demonstrated favorable response rates with no unexpected immune-related toxicities in phase I/II clinical trials.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Amin N, Maroun CA, El Asmar M, et al. Neoadjuvant immunotherapy prior to surgery for mucosal head and neck squamous cell carcinoma: Systematic review. Head Neck. 2021. PMID: 34825751. doi:10.1002/hed.26935

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。